Predictors of response to omalizumab for chronic spontaneous urticaria: a retrospective audit on a rural and regional patient cohort in Darwin, Australia
Internal Medicine Journal · 2026
DOI: 10.1111/imj.70286 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal Medicine Journal, 2026. Verfasst von Nathaniel Triffitt und 1 weiteren Autor:innen. Beteiligte Einrichtung: Immunology Department, Royal Darwin Hospital, Darwin, Northern Territory, Australia. Hauptthemen laut MEDLINE: Omalizumab, Chronic Urticaria, Rural Population, Anti-Allergic Agents. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
This review of omalizumab use in chronic spontaneous urticaria (CSU) over a 9‐year period in a rural setting identified that a ‘complete response’ to 3 months of omalizumab treatment was associated with an elevated IgE level, absence of other autoimmune diseases and older age, compared with a ‘partial response’. Median CSU duration was 36 months prior to omalizumab. There is insufficient evidence to recommend routine IgE testing to predict omalizumab response as it is unlikely to change management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Immunology Department, Royal Darwin Hospital, Darwin, Northern Territory, Australia.
ORCID-Profile: Nathaniel Triffitt
Zitieren
APA
Triffitt, N., & Tan, J. A. (2026). Predictors of response to omalizumab for chronic spontaneous urticaria: a retrospective audit on a rural and regional patient cohort in Darwin, Australia. Internal Medicine Journal. https://doi.org/10.1111/imj.70286
Vancouver
Triffitt N, Tan JA. Predictors of response to omalizumab for chronic spontaneous urticaria: a retrospective audit on a rural and regional patient cohort in Darwin, Australia. Internal Medicine Journal. 2026. doi:10.1111/imj.70286
BibTeX
@article{Triffitt2026,
author = {Triffitt, Nathaniel and Tan, Ju Ann},
title = {Predictors of response to omalizumab for chronic spontaneous urticaria: a retrospective audit on a rural and regional patient cohort in Darwin, Australia},
journal = {Internal Medicine Journal},
year = {2026},
doi = {10.1111/imj.70286}
}
EUVIMED